A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Advanced Solid TumorMetastatic Solid Tumors
Interventions
DRUG

Raludotatug deruxtecan

IV administration Q3W

Trial Locations (48)

2100

RECRUITING

Herlev og Gentofte Hosp, Copenhagen

2610

RECRUITING

ZAS Sint-Augustinus, Wilrijk

3000

RECRUITING

UZ Leuven Gynaec onco, Leuven

10065

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

10408

RECRUITING

National Cancer Center, Goyang-si

11590

RECRUITING

Clinical Research Alliance, Westbury

12208

RECRUITING

Women's Cancer Care Associates, Albany

14000

RECRUITING

François Baclesse Center, Caen

15006

RECRUITING

Hospital Universitario de A Coruña, A Coruña

16132

RECRUITING

Irccs Ospedale San Martino, Genova

20132

RECRUITING

IRCCS San Raffaele, Milan

21079

RECRUITING

Centre Georges-François Leclerc, Dijon

22190

RECRUITING

Cario - Centre Armoricain de Radiothérapie, Imagerie Médicale Et Oncologie, Plérin

28027

RECRUITING

The Clínica Universidad de Navarra Madrid, Madrid

28033

RECRUITING

Md Anderson Cancer Centre, Madrid

28041

RECRUITING

Hospital 12 Octubre, Madrid

29010

RECRUITING

Hospital Universitario Virgen de la Victoria, Málaga

30060

RECRUITING

Northside Hospital, Marietta

31100

RECRUITING

Institut Claudius Regaud, Toulouse

38138

RECRUITING

West Cancer Center and Research Institute, Germantown

40121

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

44805

RECRUITING

Ico - Site René Gauducheau, Saint-Herblain

47014

RECRUITING

IRCCS Dino Amadori - IRST, Meldola

48109

RECRUITING

University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor

69008

RECRUITING

Centre Leon Berard, Lyon

75012

RECRUITING

Grp Hsp Diac Croix Saint Simon, Paris

77030

NOT_YET_RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80131

RECRUITING

Federico II Hospital, Naples

94800

RECRUITING

Gustave Roussy, Villejuif

95126

RECRUITING

AO per lEmergenza Cannizzaro, Catania

200000

RECRUITING

Shanghai Cancer center, Shanghai

410013

RECRUITING

Hunan Cancer Hospital, Changsha

08816

RECRUITING

Astera Cancer Care, East Brunswick

59 000

RECRUITING

Centre Oscar Lambret, Lille

05100

RECRUITING

Azienda Ospedaliera S Maria, Terni

13-70

RECRUITING

Hyogo Cancer Center, Akashi

104-0045

RECRUITING

National Cancer Center Hospital, Chūōku

811-1395

RECRUITING

National Hospital Organization Kyushu Cancer Center, Fukuoka

1397-1

RECRUITING

Saitama Medical University International Medical Center, Hidaka

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

Unknown

RECRUITING

The Cancer Institute Hospital of Jfcr, Kōtoku

464-8681

RECRUITING

Aichi Cancer Centre, Nagoya

541-8567

RECRUITING

Osaka International Cancer Institute, Osaka

03722

RECRUITING

Severance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

08035

RECRUITING

Vall d'Hebron University Hospital, Barcelona

08041

RECRUITING

Hospital de Sant Pau, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY

NCT06660654 - A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Biotech Hunter | Biotech Hunter